Article
Using POCUS of the Internal Jugular Vein to Predict Central Venous Pressure
December 1, 2022
Dr. Lawson Clinical question: Does point of care ultrasound (POCUS) of the internal jugular vein accurately predict central venous pressure? Background: Assessing volume status is critical to...
Article
Tips for Properly Documenting and Coding HF
December 1, 2022
As hospitalists, we encounter heart failure (HF) regularly, but we have all seen it documented in a variety of ways (congestive HF (CHF), acute on chronic HF, heart failure with preserved ejection...
Article
There is a Decreased Risk of Hospitalization from Heart Failure in Type II Diabetics Initiated on a SGLT2 Inhibitor When Compared to a GLP-1 Receptor Agonist
September 1, 2022
Dr. Huang Clinical question: Determine the cardiovascular risk outcome in type II diabetic patients initiated on an sodium-glucose cotransporter-2 (SGLT2) inhibitor versus a glucagon-like...
Article
How to Treat Heart Failure: New Updates
August 1, 2022
Case A 76-year-old man with a medical history of congestive heart failure (CHF) with left ventricular ejection fraction of 30%, hypertension, dyslipidemia, and recent hospitalization for CHF...
Article
Effective therapy for heart failure with preserved ejection fraction
January 7, 2022
Dr. Anderson Clinical question: What effect do sodium-glucose cotransporter 2 (SGLT2) inhibitors have on outcomes in adults with heart failure with preserved ejection fraction...
![1]()
News
New data on rare myocarditis after COVID-19 vaccination
December 8, 2021
Most adolescents and young adults recover quickly from the rare complication of myocarditis following mRNA COVID-19 vaccination, a new study shows.
![1]()
News
SGLT2 inhibitor use tied to fewer atrial arrhythmias
December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
News
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
November 19, 2021
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
![1]()
News
Empagliflozin a winner in challenging arena of stabilized acute HF
November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
![1]()
News
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
November 17, 2021
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
